v3.22.2
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue $ 0 $ 0 $ 0 $ 0
Expenses:        
Research and development 7,341 9,831 14,734 18,059
General and administrative 3,332 3,657 7,439 11,681
Operating expenses 10,673 13,488 22,173 29,740
Other income/(expense):        
Interest income 111 23 133 50
Foreign exchange gain/(loss) (3) (5) (6) (7)
Total other income 108 18 127 43
Net loss (10,565) (13,470) (22,046) (29,697)
Other comprehensive gain/(loss):        
Unrealized loss on available-for-sale securities (37) 0 (37) 0
Total comprehensive loss $ (10,602) $ (13,470) $ (22,083) $ (29,697)
Basic loss per common share (in dollars per share) $ (0.11) $ (0.15) $ (0.24) $ (0.33)
Weighted average number of common shares outstanding used in the calculation of (in thousands) basic loss per common share (in shares) 92,243 88,946 92,234 88,915
Diluted loss per common share (in dollars per share) $ (0.11) $ (0.15) $ (0.24) $ (0.33)
Weighted average number of common shares outstanding used in the calculation of (in thousands) diluted loss per common share (in shares) 92,243 88,946 92,234 88,915

Source